source
- Novartis investors grow wary as drug setbacks spark scrutiny of M&A strategyInvestors in Novartis are intensifying their examination of the company’s recent dealmaking after a series of setbacks involving drugs that were brought in through mergers and acquisitions. The hei…
- ALS research pivots to biology-driven biomarkers to capture disease heterogeneityALS drug development is moving beyond traditional measures such as survival time and the ALS Functional Rating Scale. Researchers are now adding biology‑focused approaches that aim to reflect the f…